Abstract: An unexpectedly more potent isomer of 2-amino-4,5-(1,2-cyclohexyl)-7-phosphonoheptanoic acid, a known excitatory amino acid antagonist, pharmaceutical compositions including this isomer and methods of using this isomer to antagonize excitatory amino acid receptors.

Abstract: 5,6,7,8,9,10-Hexahydro-7,10-iminocyclohept[b]indole, 6,7,8,9,10,11-hexahydro-7,11-imino-5H-cyclooct[b]indole and substituted derivatives are effective in the treatment of psychoses with limited liability to produce concomitant adverse extrapyramidal symptoms. These compounds are also useful for treating other central nervous system and cardiovascular disorders.

Abstract: The present invention relates to the efficient removal of low density lipoprotein cholesterol complex (LDL-C) from whole blood. More specifically, it relates to the use of an immobilized affinity agent on a microporous plasmapheresis membrane. The immobilized affinity agent is polyacrylic acid bound directly and/or through an interaction with silica and/or calcium chloride to a microporous hollow fiber membrane.

Abstract: A cytotoxicity test method is provided which measures the effect of test substances or physical stimulation on cells. The method is both simple and sensitive and is useful for a wide variety of substances and stimulations.

Abstract: The disclosure herein describes a bovine embryo culture medium which includes epithelial cells from the oviduct of a donor animal. Additionally, a process for maturing immature bovine oocytes in an in vitro bovine culture medium containing epithelial cells from a donor oviduct is described. As an alternative to co-culture of the embryos with the epithelial cells, it is described how a culture medium can be conditioned for the culture of bovine embryos by the culture of epithelial cells therein which are later removed.

Abstract: Compounds and compositions comprising fragments and synthetic analogs of human thrombospondin are provided together with methods for their use as thrombospondin-like agents.

Abstract: Compounds and compositions comprising fragments and synthetic analogs of human thrombospondin are provided together with methods for their use as thrombospondin-like agents.

Abstract: Compounds and compositions comprising fragments and methods for using synthetic analogs of thrombospondin for promoting or inhbiting thrombospondin-like activity are provided.

Abstract: The present invention relates to the efficient removal of low density lipoprotein cholesterol complex (LDL-C) from whole blood. More specifically, it relates to the use of an immobilized affinity agent on a microporous plasmapheresis membrane. The immobilized affinity agent is polyacrylic acid bound directly and/or through an interaction with silica and/or calcium chloride to a microporous hollow fiber membrane.

Abstract: An improved cryopreservation of embryos has been developed. After freezing in a cryoprotective solution of ethylene glycol, glycerol or a combination thereof, the embryos can be thawed and transferred directly to the recipient animal without serial rehydration. The transfer can be made directly from the cryoprotective container to the recipient animal.

Abstract: Pharmaceutical compositions and dressings useful in wound healing are provided. The pharmaceutical compositions comprise thrombospondin as the active ingredient.

Abstract: Microporous hollow fiber polysulfone membranes can be prepared continuously by using a particular combination of casting solution and precipitation solution formulations, and casting conditions. The concentration of components in the precipitation solution are adjusted continuously to maintain original concentrations. The membranes are characterized by high quality, consistent performance and uniform porosity throughout the membrane.

Abstract: Compositions and methods of use are provided for debriding and wound healing applications. The compositions contain certain proteases produced by microorganisms of the genus Vibrio.

Abstract: This nutrient medium is very effective for the serum-free or serum-protein-free culture of various animal cells, in both high and low density culture. Serum proteins have been replaced with non-protein-based cell growth enhancers and a non-serum derived protein supplement. The non-protein growth enhancer is a modified or derivatized polyurethane prepolymer of polymer and preferably is a sulfhydryl derivative of polyurethane. The protein supplement may be insulin, an insulin analog or an insulin-like growth factor.

Abstract: Neutral protease genes from Vibrio proteolyticus or Bacillus can be cloned and expressed in gram-negative microorganisms, such as E. coli or Serratia. The functional neutral protease enzyme is expressed.

Abstract: L-Serine derivatives produced by the enzyme catalyzed aldol condensation of glycine and an aldehyde in aqueous solution are recovered in high yield by extracting the aqueous product solution containing said serine derivatives with an organic phase comprising (i) an aldehyde, or (ii) mixtures of an aldehyde and a water immiscible organic solvent, followed by re-extracting the organic phase with an aqueous phase having a pH of less than about 7.0. The L-erythro isomers of L-serine derivatives such as L-phenylserine may be preferentially prepared by the use of this extraction/re-extraction procedure in combination with bioreactor reaction conditions which include a pH of from about 7.5 to 10, an aldehyde concentration of from about 1 to about 90 grams/liter, a glycine concentration of from about 10 to about 300 grams/liter, and a molar ratio of glycine to aldehyde of from about 4:1 to about 100:1.

Abstract: Microporous polysulfone membranes can be prepared by using a particular combination of casting solution and precipitation solution formulations, and casting conditions. The casting solution comprises polysulfone and a protein non-adsorptive prepolymer and the precipitation solution comprises a polymerization catalyst. Both hollow fiber and flat membranes can be prepared in this manner. The membranes are substantially protein non-adsorptive and have valuable physical characteristics including increased strength and high flux.

Abstract: Biocompatible polymers derived from isocyanate-capped high molecular weight triols and higher polyols are covalently linked to drugs. These polymer-modified drugs have one or more of the following advantages over the unmodified drug: reduction of immunogenicity of the drug, increased circulating half-life of the drug due to longer residence time in circulation, ability to administer multiple drugs together, and enhanced potency of the drug.

Abstract: The drug carrier of this invention provides a temperature-sensitive polymer chemically bonded to a drug. The drug carrier is capable of releasing a drug continuously in the body. The drug carrier is a liquid when administered and becomes solid in the body, in which state it is capable of releasing a drug continuously. The drug carrier has a lower LCST than human body temperature.

Abstract: Disclosed herein is an enzymatic process to bind two amino acids in the presence of a water-miscible solvent. Preferably the amino acids are precursors of aspartame and a preferred solvent is acetonitrile.